Loading...
THE USE OF PREVENTATIVE CANNABIDIOL, CANNABIGEROL, AND MITRAGYNINE TO AMELIORATE MECHANICAL SENSITIVITY OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY IN FEMALE MICE
Ross, Nora Dorothy
Ross, Nora Dorothy
Citations
Altmetric:
Genre
Thesis/Dissertation
Date
2025-05
Advisor
Committee member
Group
Department
Biomedical Sciences
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.34944/jjhn-k812
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect of cytotoxic chemotherapy drugs. It has been reported that >60% of patients receiving chemotherapy suffer from this debilitating condition, which manifests itself in a polyneuropathy of paresthesia, hyperalgesia, allodynia, and numbness, primarily felt in the hands and feet. With no current FDA-approved medications to treat the entirety of CIPN’s symptoms, it is essential to find solutions for this condition.
Veering away from classic prescription pharmaceuticals, pharmacological studies have favored medicinal plant–based analgesic therapies, anticipating that these approaches could offer effective pain relief. These preclinical studies have demonstrated the antiallodynic effects of Cannabidiol and Cannabigerol from Cannabis Sativa along with Mitragynine from Mitragyna Speciosa. Not only did they show reduction in mechanical allodynia, but Mitragynine studies showed promise in female-only models.
In the present set of experiments, we conduct dose-response studies using both single agents and combinations of these plant alkaloids. These studies were designed to fully evaluate the extent to which these compounds can alleviate mechanical allodynia in a chemotherapy-induced, female-only mouse model.
To further emphasize the nature of a female-only preclinical model, we employed a commonly used breast, ovarian, and cervical chemotherapy, taxane, Paclitaxel.
Description
Citation
Citation to related work
Has part
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu